Cognitive and Metacognitive Evaluation in VR-Based Avatar Therapy for Psychosis
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorFundació Sant Joan de Déu
About this trial
This study aims to evaluate the relationship between cognitive, metacognitive and social cognition variables in patients with psychosis undergoing VR-based Avatar Therapy for the treatment of auditory hallucinations. In addition to the primary intervention, participants will be assessed using validated tools for emotion recognition, attributional style, theory of mind, neurocognition, and metacognition. The study also explores the potential role of trauma as a predisposing factor. Assessments will be conducted at four time points: screening (week 0), baseline (week 12), intervention period (weeks 12-24), and post-therapy follow-up (week 24). By investigating these variables, this study seeks to better understand their impact on treatment outcomes and contribute to the development of personalized therapeutic approaches.
Eligibility criteria
Qualifiers
Adults aged 18 years or older.
Diagnosis of schizophrenia spectrum disorder according to DSM-5 criteria.
Experience of persistent auditory hallucinations for at least 3 months (PANSS hallucination score ≥ 3).
Stable medication dosage for at least 4 weeks prior to recruitment.
Disqualifiers
Inability to identify a dominant voice for Avatar Therapy intervention.
Intellectual disability based on medical history.
Active substance abuse.
Central nervous system injury or neurological disorders affecting cognitive performance.
Trial design
Treatments tested in this trial
- VR-Based Avatar Therapy with Cognitive and Metacognitive Assessments
Treatment groups
30 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov